ERBB2 and cancer: However, considering the correlation between HER2 mRNA and HER2 protein we only found in ER-negative BCs, it stands to reason that in ER-positive tumors, HER2 mRNA, which was found to be regulated by several transcription factors in HER2-negative BCs [37], reflects other signals, which are relevant in cancer sensitivity to trastuzumab, independently of the number of receptors on the cell membrane.